Finance

Lists
CHGCY:OTCMKTS
Chugai Pharmaceutical ADR
$20.75
+1.17%
(+0.24) 1D
Sep 11, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CHGCY...
Open
$21.63
High
$21.63
Low
$20.02
Mkt. cap
10.78T
Avg. vol.
207.71K
Volume
271.74K
52-wk high
$34.84
52-wk low
$20.02
Beta
0.57
Shares outstanding
3.36B
No. of employees
5K
Open
$21.63
High
$21.63
Low
$20.02
Mkt. cap
10.78T
Avg. vol.
207.71K
Volume
271.74K
52-wk high
$34.84
52-wk low
$20.02
Beta
0.57
Shares outstanding
3.36B
No. of employees
5K
Profile
Chugai Pharmaceutical Co., Ltd. is a drug manufacturer operating in Japan. It is a subsidiary controlled by Hoffmann-La Roche, which owns 62% of the company as of 30 June 2014. The company is headquartered in Tokyo. Osamu Nagayama is the current representative director and chairman. Tatsuro Kosaka is the current representative director, president and CEO. Wikipedia
About Chugai Pharmaceutical ADR
CEOOsamu Okuda
Employees5.1K
FoundedMar 10, 1925
Headquarters-
SectorPharmaceutical industry
Websitechugai-pharm.co.jp
Previous reportsAll values in JPY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in JPY
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
333.18B
346.30B
321.75B
341.58B
Cost of goods sold
100.24B
87.56B
92.79B
104.22B
Cost of revenue
100.24B
87.56B
92.79B
104.22B
Research and development expenses
48.60B
52.41B
41.89B
47.76B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
27.89B
36.92B
28.90B
29.04B
Operating expense
76.45B
89.74B
70.19B
76.51B
Total operating expenses
176.69B
177.30B
162.98B
180.73B
Operating income
156.48B
169.01B
158.76B
160.86B
Other non operating income
-356.00M
994.00M
1.43B
3.04B
EBT including unusual items
156.07B
169.90B
160.20B
169.02B
EBT excluding unusual items
156.07B
169.90B
160.20B
169.02B
Income tax expense
44.86B
41.50B
44.78B
52.69B
Effective tax rate
28.74%
24.42%
27.95%
31.17%
Other operating expenses
-38.00M
405.00M
-596.00M
-291.00M
Net income
111.21B
128.41B
115.42B
116.33B
Net profit margin
33.38%
37.08%
35.87%
34.06%
Earnings per share
-
-
-
-
Interest and investment income
-
-
-
5.13B
Interest expense
-58.00M
-95.00M
-
-
Net interest expenses
-58.00M
-95.00M
-
5.13B
Depreciation and amortization charges
-
-
-
-
EBITDA
156.78B
200.44B
159.26B
161.56B
Gain or loss from assets sale
-
4.53B
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps